Fulgent Genetics Inc (FLGT) Stock Price, Quote & News

Company Profile

Fulgent Genetics, Inc. provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company's clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer serv...

Industry: Diagnostics & Research

Sector: Healthcare

Phone: 626 350 0537

Fax: 626 454 1667

Website: www.fulgentgenetics.com

Address:

4399 Santa Anita Avenue, El Monte, United States

jf152 Jul. 14 at 8:03 PM

Why did @Sexydream lie? Only evil people lie. $FLGT went UP today.

0 · Reply

jf152 Jul. 13 at 9:10 PM

$FLGT What kind of unhinged liar acts like this over a 13 cent decline?

1 · Reply

Sexydream Jul. 13 at 3:55 PM

$FLGT @jf152 When will you listen to daddy. At this point haven't I proved enough times I'm never wrong?! What happened to your $100 a share prediction??. 🤣🤣🤣🤣 More like $10 incoming

0 · Reply

Estimize Jul. 13 at 10:15 AM

Wall St is expecting -0.46 EPS for $FLGT Q2 [Reporting 07/31 BMO] http://www.estimize.com/intro/flgt?chart=historical&metric_name=eps&utm_c

0 · Reply

mfglola Jul. 11 at 4:22 PM

$FLGT Perhaps a BTD for FID-007 in r/m HNSCC is in the works. J&J received BTD for amivantamab in the same setting earlier this year. Fulgent's results are comparable with a higher ORR, albeit amivantamab is targeting HPV unrelated tumors whereas FID-007 targets the broader population.

0 · Reply

mfglola Jul. 10 at 12:57 AM

$FLGT Q2 earnings call set for Thursday, July 30 after market. Typically they release on Fridays, premarket. Significant news perhaps?

1 · Reply

Sexydream Jul. 9 at 5:58 PM

$FLGT "This price movement doesn't count. It's low volume. It's nothing but manipulation" - @jf152 🤡 He said it himself. This rise doesn't count. Idiot

1 · Reply

jf152 Jul. 6 at 8:27 PM

$FLGT Up over 32% since this post.

2 · Reply

jf152 Jul. 6 at 8:26 PM

$FLGT Now up over 20% since this post.

0 · Reply

Sexydream Jun. 30 at 8:11 PM

$FLGT @jf152 Let me remind you how big a LOSER you are. YTD Flgt: -22% Russell 2000 index: +21% 1 year Flgt: +3% Russell 2000 index: +40% 5 year Flgt: -78% R2000 index: +30% LOSER, your speculative junk stock is getting rocked by the INDEX!! 🤣🤣🤣🤣🤣 Stop investing. You're the biggest loser in the interwebz. You SUCK

1 · Reply

Fulgent to Announce Second Quarter 2026 Financial Results on Thursday, July 30, 2026

2026-06-02T00:00:19.000Z - 6 weeks ago

Fulgent Genetics presents updated FID-007 data at ASCO 2026

Jun 1, 2026, 7:00 PM EDT - 6 weeks ago

Fulgent Presents Updated FID-007 Data at ASCO 2026

May 22, 2026, 3:14 PM EDT - 7 weeks ago

Lowey Dannenberg, P.C. is Investigating Fulgent Genetics Inc. (NASDAQ: FLGT) for Potential Violations of the Federal Securities Laws and Encourages Investors to Contact the Firm

May 21, 2026, 5:03 PM EDT - 7 weeks ago

Fulgent Announces Rapid Oral Full Abstract Publication for FID-007 Within the Head and Neck Cancer Track Session at the ASCO 2026 Annual Meeting

May 20, 2026, 8:28 AM EDT - 7 weeks ago

Fulgent Genetics, Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses

2026-05-05T11:00:29.000Z - 2 months ago

Fulgent Genetics price target lowered to $15 from $30 at Piper Sandler

May 4, 2026, 7:00 AM EDT - 2 months ago

Foundation Medicine to Launch FoundationOne®PGx, a Pharmacogenetic Offering, Through Expanded Partnership with Fulgent Genetics

May 1, 2026, 8:30 AM EDT - 2 months ago

Fulgent Genetics Earnings Call Transcript: Q1 2026

May 1, 2026, 8:30 AM EDT - 2 months ago

Fulgent Genetics Earnings release: Q1 2026

May 1, 2026, 8:30 AM EDT - 2 months ago

Fulgent Genetics Slides: Q1 2026

May 1, 2026, 8:30 AM EDT - 2 months ago

Fulgent Genetics Quarterly report: Q1 2026

2026-05-01T11:33:57.000Z - 2 months ago

Fulgent Genetics reports Q1 EPS (36c) vs 4c last year

2026-05-01T11:32:59.000Z - 2 months ago

Fulgent Genetics sees FY26 EPS ($1.59)

May 1, 2026, 7:00 AM EDT - 2 months ago

Fulgent Reports First Quarter 2026 Financial Results

Apr 22, 2026, 4:05 PM EDT - 2 months ago

Fulgent Selected to Present Rapid Oral Abstract Within the Head and Neck Cancer Track Session at the 2026 ASCO Annual Meeting

Apr 16, 2026, 7:30 AM EDT - 3 months ago

Fulgent to Announce First Quarter 2026 Financial Results on Friday, May 1, 2026

Mar 31, 2026, 8:00 AM EDT - 3 months ago

Fulgent Genetics Proxy statement: Proxy filing

Mar 31, 2026, 8:00 AM EDT - 3 months ago

Fulgent Genetics Proxy statement: Proxy filing

Mar 17, 2026, 4:31 PM EDT - 4 months ago

Fulgent Genetics Completes Acquisition of Bako Diagnostics and StrataDx

Mar 13, 2026, 9:00 AM EDT - 4 months ago

Fulgent Genetics, Inc. Investigated by the Portnoy Law Firm

2026-03-02T14:13:22.000Z - 4 months ago

Fulgent Genetics price target lowered to $22 from $35 at UBS

Feb 27, 2026, 8:30 AM EST - 4 months ago

Fulgent Genetics Earnings Call Transcript: Q4 2025

Feb 27, 2026, 8:30 AM EST - 4 months ago

Fulgent Genetics Annual report: Q4 2025

Feb 27, 2026, 8:30 AM EST - 4 months ago

Fulgent Genetics Earnings release: Q4 2025

Feb 27, 2026, 8:30 AM EST - 4 months ago

Fulgent Genetics Slides: Q4 2025

2026-02-27T12:27:58.000Z - 4 months ago

Fulgent Genetics reports Q4 EPS 16c, consensus 3c

2026-02-27T12:26:02.000Z - 4 months ago

Fulgent Genetics sees FY26 EPS ($1.45), consensus (32c)

Feb 27, 2026, 7:00 AM EST - 4 months ago

Fulgent Reports Fourth Quarter and Full Year 2025 Financial Results

Feb 12, 2026, 7:30 AM EST - 5 months ago

Fulgent to Announce Fourth Quarter and Full Year 2025 Financial Results on Friday, February 27, 2026

2025-12-22T21:15:30.000Z - 7 months ago

Fulgent Genetics to acquire Bako Diagnostics and StrataDx

Dec 22, 2025, 4:10 PM EST - 7 months ago

Fulgent Genetics Agrees to Acquire Bako Diagnostics and StrataDx

Dec 2, 2025, 11:00 AM EST - 8 months ago

Fulgent Genetics Transcript: Piper Sandler 37th Annual Healthcare Conference

2025-11-11T11:41:19.000Z - 8 months ago

Fulgent Genetics price target raised to $30 from $21 at Piper Sandler

Nov 10, 2025, 5:00 PM EST - 8 months ago

Fulgent Genetics Transcript: UBS Global Healthcare Conference 2025

Nov 7, 2025, 4:05 PM EST - 8 months ago

Fulgent to Participate in Upcoming Conferences

Nov 7, 2025, 8:30 AM EST - 8 months ago

Fulgent Genetics Earnings Call Transcript: Q3 2025

Nov 7, 2025, 8:30 AM EST - 8 months ago

Fulgent Genetics Quarterly report: Q3 2025

Nov 7, 2025, 8:30 AM EST - 8 months ago

Fulgent Genetics Earnings release: Q3 2025

Nov 7, 2025, 8:30 AM EST - 8 months ago

Fulgent Genetics Slides: Q3 2025

2025-11-07T12:21:18.000Z - 8 months ago

Fulgent Genetics reports Q3 EPS (21c), consensus (22c)

2025-11-07T12:20:20.000Z - 8 months ago

Fulgent Genetics raises FY25 EPS view to 30c from (35c), consensus (35c)

Nov 7, 2025, 7:05 AM EST - 8 months ago

Fulgent Reports Third Quarter 2025 Financial Results

2025-10-20T10:10:54.000Z - 9 months ago

Fulgent Genetics announces preliminary data from Phase 2 study of FID-007

Oct 20, 2025, 6:00 AM EDT - 9 months ago

Fulgent Shares Preliminary Data from Poster Presentation at ESMO 2025 Conference

Oct 16, 2025, 7:00 AM EDT - 9 months ago

Fulgent to Announce Third Quarter 2025 Financial Results on Friday, November 7, 2025

2025-08-05T09:30:12.000Z - 1 year ago

Fulgent Genetics upgraded to Buy from Neutral at UBS

2025-08-04T10:45:28.000Z - 1 year ago

Fulgent Genetics price target lowered to $21 from $23 at Piper Sandler

Aug 1, 2025, 8:30 AM EDT - 1 year ago

Fulgent Genetics Earnings Call Transcript: Q2 2025

Aug 1, 2025, 8:30 AM EDT - 1 year ago

Fulgent Genetics Quarterly report: Q2 2025

Aug 1, 2025, 8:30 AM EDT - 1 year ago

Fulgent Genetics Earnings release: Q2 2025

Aug 1, 2025, 8:30 AM EDT - 1 year ago

Fulgent Genetics Slides: Q2 2025

2025-08-01T11:20:58.000Z - 1 year ago

Fulgent Genetics reports Q2 EPS 7c, consensus (18c)

2025-08-01T11:20:17.000Z - 1 year ago

Fulgent Genetics raises FY25 EPS view to (35c) from (65c), consensus (55c)

Aug 1, 2025, 7:00 AM EDT - 1 year ago

Fulgent Reports Second Quarter 2025 Financial Results

Jul 17, 2025, 7:00 AM EDT - 1 year ago

Fulgent Genetics Receives EU CE Mark for FulgentExome & FulgentPLM

Jul 10, 2025, 4:05 PM EDT - 1 year ago

Fulgent to Announce Second Quarter 2025 Financial Results on Friday, August 1, 2025

May 2, 2025, 8:30 AM EDT - 1 year ago

Fulgent Genetics Earnings Call Transcript: Q1 2025

May 2, 2025, 8:30 AM EDT - 1 year ago

Fulgent Genetics Quarterly report: Q1 2025

May 2, 2025, 8:30 AM EDT - 1 year ago

Fulgent Genetics Earnings release: Q1 2025

May 2, 2025, 7:00 AM EDT - 1 year ago

Fulgent Reports First Quarter 2025 Financial Results

May 2, 2025, 7:00 AM EDT - 1 year ago

Fulgent Genetics Slides: Investor Presentation

Apr 10, 2025, 4:05 PM EDT - 1 year ago

Fulgent to Announce First Quarter 2025 Financial Results on Friday, May 2, 2025

Mar 26, 2025, 8:00 AM EDT - 1 year ago

Fulgent Genetics Proxy statement: Proxy Filing

Mar 25, 2025, 8:00 AM EDT - 1 year ago

Fulgent Genetics Proxy statement: Proxy Filing

Feb 28, 2025, 8:30 AM EST - 1 year ago

Fulgent Genetics Earnings Call Transcript: Q4 2024

Feb 28, 2025, 8:30 AM EST - 1 year ago

Fulgent Genetics Annual report: Q4 2024

Feb 28, 2025, 8:30 AM EST - 1 year ago

Fulgent Genetics Earnings release: Q4 2024

Feb 28, 2025, 7:00 AM EST - 1 year ago

Fulgent Reports Fourth Quarter and Full Year 2024 Financial Results

Feb 28, 2025, 7:00 AM EST - 1 year ago

Fulgent Genetics Slides: Investor Presentation

Feb 6, 2025, 4:05 PM EST - 1 year ago

Fulgent to Announce Fourth Quarter and Full Year 2024 Financial Results on Friday, February 28, 2025

Feb 4, 2025, 4:00 PM EST - 1 year ago

Foundation Medicine to Launch Hereditary Germline Tests, FoundationOne®Germline and FoundationOne®Germline More, in the United States Through a Partnership with Fulgent Genetics

Dec 4, 2024, 11:30 AM EST - 1 year ago

Fulgent Genetics Transcript: Piper Sandler 36th Annual Healthcare Conference

Nov 12, 2024, 5:45 PM EST - 1 year ago

Fulgent Genetics Transcript: UBS Global Healthcare Conference 2024

Nov 8, 2024, 8:30 AM EST - 1 year ago

Fulgent Genetics Earnings Call Transcript: Q3 2024

Nov 8, 2024, 8:30 AM EST - 1 year ago

Fulgent Genetics Quarterly report: Q3 2024

Nov 8, 2024, 8:30 AM EST - 1 year ago

Fulgent Genetics Earnings release: Q3 2024

Nov 8, 2024, 8:30 AM EST - 1 year ago

Fulgent Genetics Slides: Q3 2024

Nov 8, 2024, 7:00 AM EST - 1 year ago

Fulgent Reports Third Quarter 2024 Financial Results

Oct 31, 2024, 8:00 AM EDT - 1 year ago

Fulgent Genetics Awarded Contract by the U.S. Department of Veterans Affairs to Provide Hereditary Cancer, Pharmacogenetic and Other Genetic Testing to Veterans1

jf152 Jul. 14 at 8:03 PM

Why did @Sexydream lie? Only evil people lie. $FLGT went UP today.

0 · Reply

jf152 Jul. 13 at 9:10 PM

$FLGT What kind of unhinged liar acts like this over a 13 cent decline?

1 · Reply

Sexydream Jul. 13 at 3:55 PM

$FLGT @jf152 When will you listen to daddy. At this point haven't I proved enough times I'm never wrong?! What happened to your $100 a share prediction??. 🤣🤣🤣🤣 More like $10 incoming

0 · Reply

Estimize Jul. 13 at 10:15 AM

Wall St is expecting -0.46 EPS for $FLGT Q2 [Reporting 07/31 BMO] http://www.estimize.com/intro/flgt?chart=historical&metric_name=eps&utm_c

0 · Reply

mfglola Jul. 11 at 4:22 PM

0 · Reply

mfglola Jul. 10 at 12:57 AM

$FLGT Q2 earnings call set for Thursday, July 30 after market. Typically they release on Fridays, premarket. Significant news perhaps?

1 · Reply

Sexydream Jul. 9 at 5:58 PM

$FLGT "This price movement doesn't count. It's low volume. It's nothing but manipulation" - @jf152 🤡 He said it himself. This rise doesn't count. Idiot

1 · Reply

jf152 Jul. 6 at 8:27 PM

$FLGT Up over 32% since this post.

2 · Reply

jf152 Jul. 6 at 8:26 PM

$FLGT Now up over 20% since this post.

0 · Reply

Sexydream Jun. 30 at 8:11 PM

1 · Reply

jf152 Jun. 30 at 1:18 PM

$FLGT Look at this moron!

0 · Reply

jf152 Jun. 29 at 8:02 PM

$FLGT 5 consecutive up days. Up 15.08% What now @sexydream ?

0 · Reply

jf152 Jun. 27 at 12:17 AM

$FLGT up 10.89% on the week with heavy Friday volume. This guy LIED on Monday despite it being obvious what was going to happen.

0 · Reply

jf152 Jun. 26 at 2:55 PM

$FLGT Only an idiot or a dishonest bad actor posts AI slop as if it means something

0 · Reply

Sexydream Jun. 25 at 3:26 PM

$FLGT https://finance.yahoo.com/markets/stocks/articles/fulgent-genetics-flgt-stock-faces-060732378.html

1 · Reply

Endergast07 Jun. 24 at 7:55 PM

$FLGT is just very uncorrelated to the market at the moment. I guess it is a wait and see time...

2 · Reply

jf152 Jun. 23 at 8:21 PM

$FLGT Russell 1000 down 1.34% today, Fulgent up 1.91%. It's almost like it irrelevant comparisons are only made by COMPLETE MORONS.

1 · Reply

Sexydream Jun. 22 at 8:13 PM

$FLGT @jf152 Russell 1000 small cap index up 1%. Junk stock flgt down 1%. How is your "INVESTING" going? 🤣🤣🤣 I can literally copy and paste my last post as the story is same every single day. Index up. Junk flgt down. How retarded can you be still holding this. Loooollllll

1 · Reply

Sexydream Jun. 17 at 7:23 PM

$FLGT 5 consecutive down day for this junk. @jf152 how does it feel being a loser? 🤣

1 · Reply

jf152 Jun. 16 at 4:53 PM

$FLGT remember he's a stupid lying troll. A terrible human. $100 in three years or less.

1 · Reply

Sexydream Jun. 16 at 4:53 PM

$FLGT 7 down days in the past 8 sessions. Market all time highs while this junk is Down 40% YTD. Down 85% in the last 5 years. Which 🤡 is holding this junk?! You must hate money. This will be at 15-20 in 3 yrs and @jf152 will still be holding saying "100 in a year!" 🤣🤣🤣

0 · Reply

Sexydream Jun. 15 at 5:43 PM

$FLGT @jf152 Markets FLYING again and flgt junk stock down. Hahahahaha How's your "investing" going??? People are making trillions of dollars. You = LOSING

0 · Reply

Market Cap	579.95M
Revenue (ttm)	322.67M
Net Income (ttm)	-60.51M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-18.75%
Debt to Equity Ratio	0.00

Volume	254,300
Avg Vol	460,772
Day's Range	N/A - N/A
Shares Out	28.40M
Stochastic %K	28%
Beta	0.89
Analysts	Hold
Price Target	$15.00